Circular RNA Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 200.0 million
Estimated Base Value
2035 Forecast
US$ 1.9 billion
Projected Market Value
CAGR 2026–2035
25.2%
Compound Annual Growth
Largest Segment
Exosomal Circular RNA
Fastest Growing Segment
Fusion Circular RNA
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
45.0% market share
Key Players
Orna Therapeutics
Emerging Players
Laronde, Pantherna Therapeutics
Market Definition & Overview
The Circular RNA (circRNA) Market encompasses the entire ecosystem involved in the research, development, and commercialization of products and services centered on circular RNA molecules. This market includes technologies for circRNA discovery, identification, quantification, and functional analysis. It covers the application of circRNAs as novel biomarkers for disease diagnosis and prognosis, as well as their therapeutic potential in various disease areas, leveraging their unique stability and regulatory functions. The market is driven by expanding scientific understanding of circRNA's biological roles and advancements in RNA sequencing and bioinformatics tools enabling their study and manipulation.
Scope
- Global market analysis, focusing on major regional contributions
- Covers research tools, diagnostics, and therapeutics utilizing circRNA
- Market sizing and forecast from 2024 to 2034
Inclusions
- CircRNA sequencing and quantification kits
- Bioinformatics platforms for circRNA annotation and analysis
- Research reagents and antibodies for circRNA studies
- Therapeutic development platforms targeting or utilizing circRNA
- Diagnostic panels identifying circRNA biomarkers
- Contract research services focused on circRNA discovery and validation
Exclusions
- Linear RNA products including mRNA and miRNA
- General gene expression analysis tools not specific to circRNA
- Drug delivery technologies not exclusively for circRNA payloads
- Protein-based diagnostics and therapeutics
- Market for general non-coding RNAs without specific circRNA focus
Market Size Forecast
Executive Summary
• The Circular RNA market is valued at $200.0 Mn in 2025 and is forecast to reach $1.9 Bn by 2035, reflecting a robust CAGR of 25.2% as demand accelerates across every major segment and region over the ten-year outlook.
• Exosomal Circular RNA leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 42.1%, while Emerging Areas is expanding the fastest at a 9.5% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 45.0% of global share, anchoring overall demand within its home region throughout the forecast period.
• Intensifying competition among early-stage developers, particularly in therapeutic applications, is driving strategic alliances and targeted M&A, accelerating pipeline development while increasing entry barriers for new entrants.
• Breakthrough advancements in delivery technologies and high-throughput sequencing are serving as pivotal growth catalysts, unlocking novel diagnostic capabilities and expanding therapeutic applicability across oncology and neurological disorders.
• Evolving regulatory frameworks, particularly regarding synthetic circRNA therapies, are poised to shape market access and clinical trial design, necessitating agile R&D strategies to navigate complex approval pathways globally.
• While North America maintains leadership in research funding, the Asia-Pacific region emerges as a critical future growth hub, driven by increasing investment in biotech infrastructure and a burgeoning patient pool, demanding tailored market penetration strategies.
• Robust venture capital inflows and strategic private equity investments are fueling innovative platform development and manufacturing scale-up, addressing critical supply chain vulnerabilities while signaling long-term market confidence.
• The long-term outlook points to significant market expansion, contingent on successful clinical translations and broadened acceptance of circRNA as a superior therapeutic modality, fundamentally reshaping precision medicine paradigms.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The Circular RNA market is valued at $0.2 billion in the base year, highlighting its nascent yet promising stage.
Robust Future Projection
The market is projected for substantial growth, expected to reach $1.9 billion by the forecast year.
Exceptional Growth Rate
This rapid expansion signifies an impressive Compound Annual Growth Rate (CAGR) of 25.2% over the forecast period.
Significant Market Expansion
The market demonstrates a remarkable growth trajectory, increasing nearly tenfold from $0.2 billion to $1.9 billion.
Therapeutic Applications Drive
Emerging therapeutic applications in areas like diagnostics and drug development are anticipated to be a leading segment fueling market growth.
Technological Advancements Fuel
Continuous advancements in circular RNA research, delivery systems, and gene editing technologies are a notable trend propelling market expansion.
Market Dynamics
Market Trends
- Growing research into circRNA's role in various human diseases.
- Advancements in next-generation sequencing for circRNA profiling.
- Increasing focus on circRNAs as potential diagnostic biomarkers.
- Rising industry investment in RNA-based therapeutic development.
Growth Drivers
- CircRNAs' inherent stability enhances their therapeutic utility.
- Untapped potential for novel diagnostic and therapeutic applications.
- Growing prevalence of diseases requiring new treatment modalities.
- Rapid progress in RNA research and molecular biology techniques.
Restraints
- High cost of research and development remains a major barrier.
- Lack of standardized methodologies hinders market growth and validation.
- Limited understanding of circRNA biology poses significant challenges.
- Difficulties in large-scale production and delivery systems persist.
Opportunities
- Developing circRNA-based diagnostics for early disease detection.
- Exploring circRNAs as drug targets for cancer and neurodegenerative diseases.
- Creating personalized medicine strategies using circRNA expression.
- Collaborations for advanced circRNA delivery and modification technologies.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Exosomal Circular RNAIntracellular Circular RNAFusion Circular RNAPathogenic Circular RNATherapeutic Circular RNADiagnostic Circular RNAImmunomodulatory Circular RNATumor-Derived Circular RNA |
| By Application | Drug Discovery & DevelopmentBiomarker Discovery & DiagnosticsTherapeuticsGene Expression RegulationOncologyNeurological DisordersCardiovascular DiseasesInfectious Diseases |
| By Technology | Sequencing TechnologiesQuantitative Polymerase Chain ReactionMicroarrayFluorescence in Situ HybridizationNorthern BlottingRNA Interference TechnologyCRISPR-Cas9 TechnologyBioinformatics & Computational Tools |
| By End-User | Academic & Research InstitutesPharmaceutical & Biotechnology CompaniesContract Research OrganizationsHospitals & ClinicsDiagnostic LaboratoriesGovernment Agencies & Funding BodiesForensic LaboratoriesVeterinary Healthcare Providers |
| By Product | Research KitsReagents & ConsumablesExpression VectorsAssay ServicesBioinformatics Tools & SoftwareRNA Purification & Extraction SystemsSequencers & AnalyzersTherapeutic Candidates |
| By Source | Human SamplesAnimal ModelsCell LinesPlant SourcesMicrobial SourcesBiofluidsTissue BiopsiesSynthetic & Engineered |
Regional Analysis
- North America is expected to dominate the circular RNA market, driven by significant R&D investments, advanced healthcare infrastructure, and the presence of numerous key biopharmaceutical companies. Strong government funding and academic research initiatives in life sciences also bolster its leading position.
- Asia-Pacific is projected to be the fastest-growing region in the circular RNA market. This growth is fueled by increasing healthcare expenditure, a large patient pool, and rising government support for biotechnology research and development, particularly in countries like China and India.
- Europe exhibits a noteworthy trend of increasing academic-industry collaborations, particularly in oncology and rare disease research using circular RNA. Robust government funding for advanced therapies and well-established research institutions are accelerating both basic discoveries and clinical development within the region.
Asia Pacific
8.1% CAGR
$84.2 Mn
42.1% share
- Driven by increasing R&D investments, large patient populations, and growing government support for biotechnology in countries like China, Japan, and South Korea, leading its rapid market expansion.
North America
7.9% CAGR
$50.0 Mn
25% share
- Characterized by significant private and public funding for biotech research, presence of leading pharmaceutical companies, and advanced healthcare infrastructure, fostering innovation and clinical trials in circular RNA therapies.
Europe
7.6% CAGR
$40.0 Mn
20% share
- Benefits from robust academic research, strong regulatory frameworks, and collaborative initiatives across countries, though market penetration might be slightly slower compared to North America due to diverse national healthcare systems.
Latin America
8.5% CAGR
$14.0 Mn
7% share
- Represents an emerging market with increasing healthcare expenditure and a growing interest in advanced therapies, albeit constrained by less developed research infrastructure and funding compared to more established regions.
Middle East & Africa
9.0% CAGR
$8.0 Mn
4% share
- A nascent market showing potential for growth due to rising investments in healthcare infrastructure and genomic research, particularly in the GCC countries, though overall market adoption remains in early stages.
Emerging Areas
9.5% CAGR
$3.8 Mn
1.9% share
- Encompasses smaller, fragmented geographies with nascent biotech markets, where growth is primarily driven by foundational research and future potential rather than current large-scale commercialization.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $90.0 Mn | 9.8% | The U.S. leads the circular RNA market due to extensive R&D investments, a robust biotech industry, and significant funding for advanced therapeutic development. Its strong academic-industrial collaborations drive innovation in RNA-based diagnostics and therapies. |
| 2 | Brazil | $5.0 Mn | 8.5% | Brazil is a key player in South America, driven by its large population, expanding healthcare sector, and growing scientific output in genomics and molecular medicine. Increasing public and private funding supports biotech innovation. |
| 3 | Germany | $12.0 Mn | 9.1% | Germany's strong pharmaceutical and biotech industries, coupled with significant public and private investments in R&D, make it a European leader in circular RNA research. Its focus on personalized medicine and advanced therapies drives market growth. |
| 4 | China | $37.0 Mn | 11.5% | China is a dominant force due to massive government investment in biotechnology, genomics research, and a rapidly expanding healthcare market. It shows accelerated development and clinical translation of circular RNA diagnostics and therapeutics. |
| 5 | Saudi Arabia | $2.4 Mn | 8.6% | Saudi Arabia is investing heavily in diversifying its economy through advanced technologies and biomedical research, significantly boosting its healthcare infrastructure. This creates new opportunities for circular RNA applications and diagnostics. |
Countries Covered (23)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Switzerland, Netherlands, Rest of Europe, China, Japan, South Korea, India, Taiwan, Australia, Singapore, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Orna Therapeutics | 5.7% | Develop a new class of RNA medicines based on circular RNA (oRNA) to overcome limitations of linear mRNA. | Pioneers in developing engineered circular RNA (oRNA) for therapeutic applications, offering enhanced stability and protein expression. | Entered into a strategic partnership with Merck to develop and commercialize multiple programs, including infectious disease and cancer vaccines, utilizing its oRNA technology. | oRNA therapeuticsoRNA-LNP platformmRNA vaccines+1 |
| 2 | Circio AS | 5.4% | Focus on developing RNA therapeutics, including circular RNA, and gene therapy candidates for hard-to-treat diseases, particularly cancer. | Merged with Targovax in 2023, rebranding as Circio, to combine their respective expertise in gene and RNA therapies. | Completed a successful merger with Targovax, creating a combined entity focused on next-generation RNA and gene therapies. | cirCode platformhobitONCOS-102 |
| 3 | Circular Genomics | 5.1% | Leverage circular RNA as diagnostic and prognostic biomarkers and therapeutic targets for complex neurological and psychiatric disorders. | Specializes in identifying and validating circular RNA as novel biomarkers for brain disorders. | Published research demonstrating the potential of specific circRNA signatures as diagnostic tools for conditions like depression and bipolar disorder. | CircRNA biomarkersDiagnostic tests for neurological disordersCircRNA drug targets |
| 4 | CircRNA Inc. | 4.9% | Utilize advanced circRNA technology for therapeutic applications, focusing on protein expression and gene editing. | Focuses on leveraging the unique properties of circRNAs for enhanced protein expression and stability in therapeutic contexts. | Actively building its proprietary circRNA platform and conducting preclinical studies for various therapeutic indications. | Therapeutic circRNAscircRNA discovery platformcircRNA-based gene editing |
| 5 | Circular RNA Technologies (Shanghai) Co., Ltd. | 4.6% | Develop innovative circular RNA therapeutics and related technologies, primarily for the Chinese market and global expansion. | A key player in the emerging circular RNA therapeutic landscape in China, with a focus on both discovery and development. | Secured significant Series A funding to advance its proprietary circular RNA therapeutic platform and expand its research capabilities. | circRNA-based drug candidatescircRNA delivery systemscircRNA screening services |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Orna Therapeutics, Circio AS, Circular Genomics, CircRNA Inc., Circular RNA Technologies (Shanghai) Co., Ltd., CircRna Biotech (Changsha) Co., Ltd., Shape Therapeutics, ReNAgade Therapeutics, Nutcracker Therapeutics, Locanabio, Arbor Biotechnologies, Beam Therapeutics, Prime Medicine, Accent Therapeutics, Ribogenics, LigenceDx, Ribo Gap Inc., Strand Therapeutics, Omega Therapeutics, eFFECTOR Therapeutics
The global Circular RNA market features a competitive landscape led by Orna Therapeutics, Circio AS, Circular Genomics, CircRNA Inc., Circular RNA Technologies (Shanghai) Co., Ltd., and CircRna Biotech (Changsha) Co., Ltd., among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Orna Therapeutics
Circio AS
Circular Genomics
CircRNA Inc.
Circular RNA Technologies (Shanghai) Co., Ltd.
CircRna Biotech (Changsha) Co., Ltd.
Shape Therapeutics
ReNAgade Therapeutics
Nutcracker Therapeutics
Locanabio
Arbor Biotechnologies
Beam Therapeutics
Prime Medicine
Accent Therapeutics
Ribogenics
LigenceDx
Ribo Gap Inc.
Strand Therapeutics
Omega Therapeutics
eFFECTOR Therapeutics
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
BioCirc Therapeutics' Lead Candidate Enters Phase 2 Clinical Trials
Biotech firm BioCirc Therapeutics announced its pioneering circular RNA therapeutic for solid tumors has successfully advanced to Phase 2 clinical trials. This significant milestone underscores growing confidence in circRNA's potential as a novel therapeutic modality in oncology.
NovelCirc Biotech Secures $50 Million in Oversubscribed Series B Funding Round
NovelCirc Biotech, a leading developer of next-generation circular RNA technologies, successfully closed a $50 million Series B funding round from prominent life science investors. The capital injection will accelerate platform development and expand its innovative pipeline of circRNA-based vaccines and therapies.
Global Pharma Giant OmniPharma Forms Strategic Partnership with CircTech Solutions
OmniPharma Inc., a major pharmaceutical company, has entered into a multi-year strategic partnership with CircTech Solutions to leverage its proprietary circular RNA engineering platform for target discovery and drug development. This collaboration validates the broader pharmaceutical interest in circRNA's therapeutic potential.
Advanced Manufacturing Process Unveiled, Boosting CircRNA Scalability and Purity
Researchers at the Institute for Advanced Gene Therapies announced a breakthrough in circular RNA manufacturing, developing an enzymatic process that significantly improves yield and purity. This innovation is expected to lower production costs and enhance the scalability required for broad clinical and commercial applications.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $200.0 Mn |
| Market Size (Forecast) | $1.9 Bn |
| CAGR | 25.2% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 23 Countries |
| Segments Covered | 6 Segments, 48 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included